Business Context and Reporting Period
Estrella Immunopharma, Inc. (ESLA) is a clinical-stage biopharmaceutical company developing T-cell therapies (EB103 and EB104) targeting blood cancers and solid tumors. This Form 10-Q covers the quarterly period ended March 31, 2026. The Company is classified as a non-accelerated filer, a smaller reporting company, and an emerging growth company. As of March 31, 2026, the Company had 43,034,228 shares of Common Stock outstanding.
Key Financial Metrics
| Metric | Q1 2026 | Q1 2025 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(2,292,064) | $(2,104,311) |
| Net Loss Per Share (Basic & Diluted) | $(0.05) | $(0.06) |
| Cash and Cash Equivalents (End of Period) | $1,927,404 | $421,473 |
| Net Cash Used in Operating Activities | $(6,698,010) | $(465,981) |
| Net Cash Provided by Financing Activities | $7,241,112 | $(29,462) |
| Total Assets | $3,657,198 | N/A |
| Total Liabilities | $8,927,494 | N/A |
| Accumulated Deficit | $(39,282,879) | N/A |
Note: The filing does not provide a clear value for Total Assets or Liabilities for Q1 2025 in the comparative table, only for Q1 2026 and the prior year-end (Dec 31, 2025).
Material Changes vs. Prior Period
- Financing Activity: The Company raised approximately $8.0 million in gross proceeds from a Registered Direct Offering (RDO) and concurrent private placement in January 2026. This contrasts with Q1 2025, which saw no equity financing and only minor cash outflows for stock repurchases.
- Operating Expenses: Total operating expenses increased to $2.29 million in Q1 2026 from $2.10 million in Q1 2025. General and Administrative (G&A) expenses rose by approximately $0.2 million, driven by higher legal/professional fees and a $108,627 loss from the change in fair value of derivative liabilities.
- Cash Flow: Net cash used in operating activities increased significantly to $6.7 million in Q1 2026 compared to $0.5 million in Q1 2025. This was primarily due to the settlement of approximately $4.7 million in related party liabilities (accrued milestone payments to Eureka).
- Related Party Liabilities: Accrued liability to related parties decreased from $12.4 million at year-end 2025 to $8.3 million at March 31, 2026, reflecting payments made for clinical trial milestones.
Guidance, Outlook, Risks, and Unusual Items
- Going Concern: Management has expressed substantial doubt about the Company's ability to continue as a going concern. Despite recent financing, the Company does not believe it has sufficient funds to meet working capital requirements and debt obligations for the next 12 months. Continued operations depend on raising additional debt or equity financing.
- Clinical Progress: The Company completed Phase I dosing for the STARLIGHT-1 clinical trial (EB103) in November 2025. As of March 31, 2026, ten patients had been dosed, and one Phase II patient was dosed in January 2026.
- Commitments: The Company has a Statement of Work (SOW) with Eureka Therapeutics for the STARLIGHT-1 trial with total potential fees of $33.5 million. As of March 31, 2026, approximately $8.3 million in milestone payments were accrued but unpaid.
- Derivative Liabilities: The Company recorded a $108,627 loss in Q1 2026 due to the change in fair value of derivative liabilities associated with "True-Up Shares" from 2025 securities purchase agreements. The total derivative liability balance was $465,132 as of March 31, 2026.
- Nasdaq Compliance: The Company received a notice of non-compliance with Nasdaq Listing Rule 5620(a) for failing to hold an annual shareholder meeting. An extension was granted until June 29, 2026, to regain compliance.
- Internal Controls: The Company identified a material weakness in internal control over financial reporting due to a lack of qualified full-time personnel with appropriate accounting knowledge. Remediation efforts are underway, but controls were deemed ineffective as of March 31, 2026.
Investor Verification Checklist
- Verify the sufficiency of the $1.9 million cash balance against the $8.3 million accrued liability to Eureka and ongoing burn rate.
- Confirm the timeline and terms for the upcoming joint 2025/2026 annual shareholder meeting to ensure Nasdaq compliance by June 29, 2026.
- Review the status of the STARLIGHT-1 clinical trial enrollment and the specific milestones triggering the remaining $8.3 million payment to Eureka.
- Assess the likelihood of future equity financing given the current stock price ($1.26 as of May 11, 2026) versus the $11.50 exercise price of public warrants and the $1.39 exercise price of recent private warrants.
- Monitor the remediation of the material weakness in internal controls over financial reporting.